Precigen (PGEN) Liabilities from Discontinued Operations (2018 - 2022)
Precigen's (PGEN) quarterly Liabilities from Discontinued Operations came in at 11448000.0 in Q2 2022, up 11123.53% year-on-year from N/an in Q2 2021, and down 10.92% on a QoQ basis from 12851000.0 in Q4 2021.
Precigen (PGEN) Liabilities from Discontinued Operations (2018 - 2022) Analysis & Trends
Precigen (PGEN) has 5 years of Liabilities from Discontinued Operations data on file, last reported at 11448000.0 in Q2 2022.
- On a quarterly basis, Liabilities from Discontinued Operations rose 11123.53% year-over-year to 11448000.0 in Q2 2022; TTM through Jun 2022 was 11448000.0, a 11123.53% increase from a year earlier, with the FY2021 full-year figure at 12851000.0, down 8.51% from the prior year.
- Liabilities from Discontinued Operations for Q2 2022 stood at 11448000.0, down from 12851000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for PGEN reached as high as 50538000.0 in Q4 2019 and fell as low as 102000.0 in Q2 2021.
- Historically, Liabilities from Discontinued Operations has averaged 14302285.71 across 5 years, with a median of 11448000.0 in 2022.
- Across the five-year window, Liabilities from Discontinued Operations slumped 72.21% in 2020 and soared 11123.53% in 2022, its largest moves.
- Year by year, Liabilities from Discontinued Operations stood at 10958000.0 in 2018, then jumped by 361.2% to 50538000.0 in 2019, then slumped by 72.21% to 14047000.0 in 2020, then declined by 8.51% to 12851000.0 in 2021, then decreased by 10.92% to 11448000.0 in 2022.
- Per Business Quant data, the three most recent Liabilities from Discontinued Operations figures were 11448000.0 in Q2 2022, 12851000.0 in Q4 2021, and 102000.0 in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 11.45 Mn |
| Jun 30, 2022 | 11.45 Mn |
| Dec 31, 2021 | 12.85 Mn |
| Dec 31, 2021 | 12.85 Mn |
| Jun 30, 2021 | 102,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Mar 31, 2021 | 172,000.00 |
| Mar 31, 2021 | 172,000.00 |
| Dec 31, 2020 | 14.05 Mn |
| Dec 31, 2020 | 14.05 Mn |
| Dec 31, 2019 | 50.54 Mn |
| Dec 31, 2019 | 50.54 Mn |
| Dec 31, 2018 | 10.96 Mn |
| Dec 31, 2018 | 10.96 Mn |